Medicine
Zestoretic 25 mg/20 mg tablet
Zestoretic 25 mg/20 mg tablet is a prescription medicine containing Hydrochlorothiazide and Lisinopril for oral use, marketed by Almatica Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect…
Key facts
- Active ingredient (INN)
- Hydrochlorothiazide and Lisinopril
- Brand
- Zestoretic
- Strength
- 25 mg/20 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 90 tablets
- Marketing authorisation holder
- Almatica Pharma
- Manufacturer
- Almatica Pharma
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from excessive light and humidity.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 April 2015
- Identifiers
- RxCUI 197885, 197886, 197887 +3DailyMed set ID 0d3a966f-f937-05a8-a90f-5aa52ebbd613NDC 52427-437Application NDA019888
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 90 tablet in 1 bottle | 52427-437-90 | Almatica Pharma | 15 April 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 16 February 1989 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Hydrochlorothiazide and Lisinopril 25 mg/20 mg tablet.
Other strengths and forms of Hydrochlorothiazide and Lisinopril
Clinical summary
Hydrochlorothiazide and Lisinopril is a fixed-dose combination of an angiotensin converting enzyme inhibitor and a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. It is available as tablets for oral use. MedsAcross supplies Hydrochlorothiazide and Lisinopril for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Hydrochlorothiazide and LisinoprilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zestoretic prescribing information (Almatica Pharma) · U.S. National Library of Medicine, DailyMed
Need Zestoretic 25 mg/20 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.